INDUSTRY SUPPORTED SESSION PROGRAMMES

Wednesday, 21 Sept., 2016, 12:00 - 14:00

PATIENTS IN PRACTICE WORKSHOP ​(participation per invitation only)​

Sponsored by SHIRE

Presenters: Prof. Helen Chapel (UK) and Prof. Eleonora Gambineri (IT)​

Patients in Practice is an interactive, case study based workshop, designed to provide starting physicians with an insight into some of the more challenging cases of Primary Immune Deficiency. The workshop will use patient case studies in the form of virtual mannequins, allowing the participants to meet each of the patients. Participants will also get the chance to interact throughout the workshop by using the voting and live messaging tools on a bespoke iPad app. ​


Thursday, 22 Sept., 2016, 12:00 - 13:30

INDUSTRY SYMPOSIUM 1

NEW INSIGHTS IN THE USE OF INTRAVENOUS IMMUNOGLOBULINS: HOW TO ENHANCE PID PATIENTS CLINICAL OUTCOMES?

Sponsored by LFB

Chair:​ Pr. Ewa Bernatowska (Poland) and Pr. Eduardo López Granados (Spain)

-  Introduction (LFB BIOMEDICAMENTS)
- Targeting patients safety in IVIG's development process, Dr. Philippe Paolantonacci (LFB)
- Could optimized IVIG's safety profile improve PID patients clinical outcomes? The experience from a multicenter study, Pr. Gergely Krivan (Hungary)
- Treatment options with IVIG's for the individualization of care in patients with PID, Dr. Stephen Jolles (UK)

 

Thursday, 22 Sept.,2016, 15:05 - 16:35

INDUSTRY SYMPOSIUM 2

PATIENT CENTRICITY IN PRIMARY IMMUNODEFICIENCIES (PID): ADDRESSING THE BURDEN OF TREATMENT

Sponsored by SHIRE

Chair:  Professor Reinhold E. Schmidt, Germany and  Jose Drabwell, UK

​1.     The burden of treatment in PID, Professor Carl May

2.     The choice of treatment in light of burden of treatment, Dr Joris van Montfrans

3.     Engaging patients and informing decision making, Emily Carne

4.     PID and burden of treatment: the patient story, Ian Deegan

5.     Q&A and close

 

Thursday, 22 Sept., 2016, 18:15 - 19:45

INDUSTRY SYMPOSIUM 3

THE LUNG IN PRIMARY IMMUNODEFICIENCIES: NEW CONCEPTS IN INFECTION AND INFLAMMATION

Sponsored by CSL BEHRING

Chair: Stephen Jolles, UK 

1.     Introduction Stephen Jolles, United Kingdom 

2.     Immunity/immunodeficiency of the respiratory system - 

Ulrich Baumann, Hannover, Germany
Does mucosal IgA immunity play a role in the upper and lower airways? How does IgG protect the lung? How is the respiratory system affected in CVID and XLA? A number of primary immunodeficiencies (XLA, CVID, SCID, WAS) present with mucosal manifestations: how can we treat?

3.     Assessment of the lung in PID

Pere Soler-Palacin, Barcelona, Spain
As therapy for PID improves the life expectancy of patients with PID, the prevalence of associated pulmonary complications is likely to increase. Therefore, knowledge of the detection and management of pulmonary disorders related to PIDs is critical for optimal management.

4.     Respiratory infections in PID: the serious acute and the subclinical chronic
Stephen Jolles, Cardiff, United Kingdom

​Pneumonia, previously the biggest problem in PID, is currently well controlled with IVIG/SCIG therapy. 'Less serious' and even subclinical infections of the upper and lower airways persist and may lead to progressive lung damage, including bronchiectasis. Role of viral and bacterial infections, introduction of non-infectious complication, and ways to prevent and treat lung damage will be discussed. 'Wear-off' of IVIG therapy: does it lead to progressive lung disease?


5.     Non-infectious pulmonary complication in PID. How can we treat?
John M. Routes, Milwaukee, WI, United States

Noninfectious diffuse lung disease complications, such as granulomatous and lymphoproliferative disorders, are an increasing cause of morbidity and mortality in CVID. Novel approaches for the treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) will be discussed.
6.     Q & A and discussion session Chair, all

7.     Meeting close Chair

 

Thursday, 22 Sept.,2016, 18:15 - 19:45

INDUSTRY SYMPOSIUM 4


KEEP YOUR BREATH - PROTECTING THE LUNGS IN IMMUNODEFICIENCY

​Sponsored by Octapharma

Chair: Prof. Klaus Warnatz

​Pathophysiology of lung disease beyond immunodeficiency - John Hurst, London

Topics to be covered: What can we learn from the different pathophysiologies of Airway disease and interstitial lung disease in non PID patients exemplified in specific disorders

The usefulness and short comings of current diagnostic methods to detect Airway and ILD and to measure the degree and activity of disease

Airway disease- only chronic infection? - Ulrich Baumann, , Hannover

Topics to be covered: Airway disease in PID with a special focus on antibody deficiencies

The risk for Bronchiectasis, the role of infection, specific pathogens, non infectious risk factors

Diagnostic approach

Outcome 

Interstitial lung disease – all the same? - Klaus Warnatz, CCI

Topics to be covered: ILD in PID with a special focus on antibody deficiencies

The risk for ILD, non infectious risk factors, the role of infection?

Diagnostic approach

Outcome 

Keep breathing – treatment options in PID - Isabella Quinti 

 IgGRT (trough levels, route etc), 

Additional therapies (symptomatic local therapies,

Prophylactic antibiotics

 

Friday, 23 Sept.,2016, 12:45 - 14:15

INDUSTRY SYMPOSIUM 5

PIONEERING PROGRESS IN ADA-SCID WITH GENE THERAPY

Sponsored by GSK

Chair: Luigi Naldini, Director, SR-TIGET and Sven Kili, Head of Gene Therapy Development, GSK 

Introduction Luigi Naldini, Director, SR-TIGET (Co-Chair) Sven Kili, Head of Gene Therapy Development, GSK (Co-Chair)
ADA-SCID: today and tomorrow Rohit Batta, Medical Affairs Lea Gene Therapy, GSK
The Strimvelis® experience: translating the clinical trial data into clinical practice Alessandro Aiuti, Clinical Research Coordinator, SR-TIGET and Head of Paediatric Immunohaematology, San Raffae Hospital, Milan, Italy
The Strimvelis® experience: a patient-centric treatment process Julie Venners Christensen,
Head of Global Patient Advocac Gene Therapy, GSK
Expert panel Q&A 
Meeting close Chairs

​ ​​

Keep Me Updated